McCune-Albright syndrome

Claudia E Dumitrescu1, Michael T. Collins1
1Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch, Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

McCune DJ: Osteitis fibrosa cystica: the case of a nine-year-old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism. Am J Dis Child. 1936, 52: 743-744.

Albright F, Butler AM, Hampton AO, Smith P: Syndrome characterized by osteitis fibrosa disseminata, areas, of pigmentation, and endocrine dysfunction, with precocious puberty in females: report of 5 cases. N Engl J Med. 1937, 216: 727-746.

Mastorakos G, Mitsiades NS, Doufas AG, Koutras DA: Hyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report. Thyroid. 1997, 7: 433-439.

Sherman SI, Ladenson PW: Octreotide therapy of growth hormone excess in the McCune-Albright syndrome. Journal of endocrinological investigation. 1992, 15: 185-190.

Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, Cherman N, Bianco P, Wientroub S, Robey PG, Collins MT: Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab. 2002, 87 (11): 5104-5112. 10.1210/jc.2001-012022.

Collins MT, Chebli C, Jones J, Kushner H, Consugar M, Rinaldo P, Wientroub S, Bianco P, Robey PG: Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J Bone Miner Res. 2001, 16: 806-813. 10.1359/jbmr.2001.16.5.806.

Danon M, Crawford JD: The McCune-Albright syndrome. Ergeb Inn Med Kinderheilkd. 1987, 55: 81-115.

Diaz A, Danon M, Crawford J: McCune-Albright syndrome and disorders due to activating mutations of GNAS1. J Pediatr Endocrinol Metab. 2007, 20: 853-880.

Kirk JM, Brain CE, Carson DJ, Hyde JC, Grant DB: Cushing's syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. The Journal of pediatrics. 1999, 134: 789-792. 10.1016/S0022-3476(99)70302-1.

Shenker A, Weinstein LS, Moran A, Pescovitz OH, Charest NJ, Boney CM, Van Wyk JJ, Merino MJ, Feuillan PP, Spiegel AM: Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr. 1993, 123: 509-518. 10.1016/S0022-3476(05)80943-6.

Lichtenstein LJH: Fibrous dysplasia of bone: a condition affecting one, several or many bones, graver cases of which may present abnormal pigmentation of skin, premature sexual development, hyperthyroidism or still other extraskeletal abnormalities. Arch Path. 1942, 33: 777-816.

Bianco P, Robey PG, Wientroub S: Fibrous dysplasia. Pediatric Bone: Biology and Disease. Edited by: Glorieux FH, Pettifor J, Juppner H. 2003, New York, NY: Academic Press, Elsevier, 509-539.

Collins MT: Spectrum and natural history of fibrous dysplasia of bone. J Bone Miner Res. 2006, 21 (Suppl 2): P99-P104. 10.1359/jbmr.06s219.

Collins MT, Bianco P: Fibrous dysplasia. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Edited by: Favus MJ. 2006, Washington, D.C.: American Society for Bone and Mineral Research, 415-418. 6

Collins MT, Shenker A: McCune-Albright syndrome: new insights. Curr Opin in Endocrinol and Diabetes. 1999, 6: 119-125. 10.1097/00060793-199904000-00006.

Dorfman HD, Czerniak B: Fibroosseous Lesions. Bone Tumors. Edited by: Dorfman HD, Czerniak B. 1998, St. Louis, MO: Mosby, 441-491.

Hart ES, Kelly MH, Brillante B, Chen CC, Ziran N, Lee JS, Feuillan P, Leet AI, Kushner H, Robey PG, Collins MT: Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome. J Bone Miner Res. 2007, 22: 1468-1474. 10.1359/jbmr.070511.

Leet AI, Chebli C, Kushner H, Chen CC, Kelly MH, Brillante BA, Robey PG, Bianco P, Wientroub S, Collins MT: Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. J Bone Miner Res. 2004, 19: 571-577. 10.1359/JBMR.0301262.

Ruggieri P, Sim FH, Bond JR, Unni KK: Malignancies in fibrous dysplasia. Cancer. 1994, 73: 1411-1424. 10.1002/1097-0142(19940301)73:5<1411::AID-CNCR2820730516>3.0.CO;2-T.

Blanco P, Schaeverbeke T, Baillet L, Lequen L, Bannwarth B, Dehais J: Chondrosarcoma in a patient with McCune-Albright syndrome. Report of a case. Rev Rhum Engl Ed. 1999, 66: 177-179.

Lopez-Ben R, Pitt MJ, Jaffe KA, Siegal GP: Osteosarcoma in a patient with McCune-Albright syndrome and Mazabraud's syndrome. Skeletal Radiol. 1999, 28: 522-526. 10.1007/s002560050556.

Scanlon EF, Burkett FE, Sener SF, Green OC, Traisman HS, Marr TJ, Victor TA, Crist ML: Breast carcinoma in a 11-year-old girl with Albright's syndrome. Breast. 1980, 6:

Tanabeu Y, Nakahara S, Mitsuyama S, Ono M, Toyoshima S: Breast Cancer in a Patient with McCune-Albright Syndrome. Breast Cancer. 1998, 5: 175-178.

Collins MT, Sarlis NJ, Merino MJ, Monroe J, Crawford SE, Krakoff JA, Guthrie LC, Bonat S, Robey PG, Shenker A: Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab. 2003, 88: 4413-4417. 10.1210/jc.2002-021642.

Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM: Activating mutations of the stimulatory G protein in the McCune – Albright syndrome [see comments]. N Engl J Med. 1991, 325: 1688-1695.

Schwindinger WF, Francomano CA, Levine MA: Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA. 1992, 89: 5152-5156. 10.1073/pnas.89.11.5152.

Bianco P, Riminucci M, Majolagbe A, Kuznetsov SA, Collins MT, Mankani MH, Corsi A, Bone HG, Wientroub S, Spiegel AM, Fisher LW, Robey PG: Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. J Bone Miner Res. 2000, 15: 120-128. 10.1359/jbmr.2000.15.1.120.

Idowu BD, Al-Adnani M, O'Donnell P, Yu L, Odell E, Diss T, Gale RE, Flanagan AM: A sensitive mutation-specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone. Histopathology. 2007, 50: 691-704. 10.1111/j.1365-2559.2007.02676.x.

Riminucci M, Saggio I, Robey PG, Bianco P: Fibrous dysplasia as a stem cell disease. J Bone Miner Res. 2006, 21 (Suppl 2): P125-131. 10.1359/jbmr.06s224.

Collins MT, Kushner H, Reynolds JC, Chebli C, Kelly MH, Gupta A, Brillante B, Leet AI, Riminucci M, Robey PG, Bianco P, Wientroub S, Chen CC: An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res. 2005, 20: 219-226. 10.1359/JBMR.041111.

Ippolito E, Bray EW, Corsi A, De Maio F, Exner UG, Robey PG, Grill F, Lala R, Massobrio M, Pinggera O, Riminucci M, Snela S, Zambakidis C, Bianco P: Natural history and treatment of fibrous dysplasia of bone: a multicenter clinicopathologic study promoted by the European Pediatric Orthopaedic Society. Journal of pediatric orthopaedics. 2003, 12: 155-177. 10.1097/00009957-200305000-00001.

Kelly MH, Brillante B, Collins MT: Pain in fibrous dysplasia of bone: age-related changes and the anatomical distribution of skeletal lesions. Osteoporos Int. 2007

Riminucci M, Liu B, Corsi A, Shenker A, Spiegel AM, Robey PG, Bianco P: The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks. The Journal of pathology. 1999, 187: 249-258. 10.1002/(SICI)1096-9896(199901)187:2<249::AID-PATH222>3.0.CO;2-J.

Corsi A, Collins MT, Riminucci M, Howell PG, Boyde A, Robey PG, Bianco P: Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: core biopsy studies and clinical correlations. J Bone Miner Res. 2003, 18: 1235-1246. 10.1359/jbmr.2003.18.7.1235.

Hannon TS, Noonan K, Steinmetz R, Eugster EA, Levine MA, Pescovitz OH: Is McCune-Albright syndrome overlooked in subjects with fibrous dysplasia of bone?. J Pediatr. 2003, 142: 532-538. 10.1067/mpd.2003.153.

Center for Genetic Testing. [ http://www.sfh-lab.com ]

Genome Diagnostics. [ http://www.umcutrecht.nl/subsite/genome-diagnostics/DNA-diagnostics/Gene-Tests.htm ]

Byard RW: Forensic considerations in cases of neurofibromatosis – an overview. Journal of forensic sciences. 2007, 52: 1164-1170. 10.1111/j.1556-4029.2007.00512.x.

Theos A, Korf BR: Pathophysiology of neurofibromatosis type 1. Annals of internal medicine. 2006, 144: 842-849.

Lee JS, FitzGibbon E, Butman JA, Dufresne CR, Kushner H, Wientroub S, Robey PG, Collins MT: Normal vision despite narrowing of the optic canal in fibrous dysplasia. N Engl J Med. 2002, 347: 1670-1676. 10.1056/NEJMoa020742.

Cutler CM, Lee JS, Butman JA, FitzGibbon EJ, Kelly MH, Brillante BA, Feuillan P, Robey PG, DuFresne CR, Collins MT: Long-term outcome of optic nerve encasement and optic nerve decompression in patients with fibrous dysplasia: risk factors for blindness and safety of observation. Neurosurgery. 2006, 59: 1011-1017. discussion 1017–1018

Feuillan PP, Shawker T, Rose SR, Jones J, Jeevanram RK, Nisula BC: Thyroid abnormalities in the McCune-Albright syndrome: ultrasonography and hormone studies. J Clin Endocrinol Metab. 1990, 71: 1596-1601.

Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003, 112: 683-692.

Terpstra L, Rauch F, Plotkin H, Travers R, Glorieux FH: Bone mineralization in polyostotic fibrous dysplasia: histomorphometric analysis. J Bone Miner Res. 2002, 17: 1949-1953. 10.1359/jbmr.2002.17.11.1949.

Glorieux FH, Rauch F: Medical therapy of children with fibrous dysplasia. J Bone Miner Res. 2006, 21 (Suppl 2): P110-113. 10.1359/jbmr.06s221.

Hammami MM, Hussain SS, Vencer LJ, Butt A, al-Zahrani A: Primary hyperparathyroidism-associated polyostotic fibrous dysplasia: absence of McCune-Albright syndrome mutations. J Endocrinol Invest. 1997, 20: 552-558.

Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G: Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. Journal of the American Geriatrics Society. 2007, 55: 752-757. 10.1111/j.1532-5415.2007.01161.x.

Giusti A, Barone A, Razzano M, Pizzonia M, Oliveri M, Palummeri E, Pioli G: High prevalence of secondary hyperparathyroidism due to hypovitaminosis D in hospitalized elderly with and without hip fracture. Journal of endocrinological investigation. 2006, 29: 809-813.

Reginster JY: The high prevalence of inadequate serum vitamin D levels and implications for bone health. Current medical research and opinion. 2005, 21: 579-586. 10.1185/030079905X41435.

Hashemipour S, Larijani B, Adibi H, Sedaghat M, Pajouhi M, Bastan-Hagh MH, Soltani A, Javadi E, Shafaei AR, Baradar-Jalili R, Hossein-Nezhad A: The status of biochemical parameters in varying degrees of vitamin D deficiency. Journal of bone and mineral metabolism. 2006, 24: 213-218. 10.1007/s00774-005-0674-8.

Stanton RP: Surgery for fibrous dysplasia. J Bone Miner Res. 2006, 21 (Suppl 2): P105-109. 10.1359/jbmr.06s220.

Chapurlat RD: Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res. 2006, 21 (Suppl 2): P114-119. 10.1359/jbmr.06s222.

Liens D, Delmas PD, Meunier PJ: Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet. 1994, 343: 953-954. 10.1016/S0140-6736(94)90069-8.

Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH: Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab. 2003, 88: 4569-4575. 10.1210/jc.2003-030050.

Chan B, Zacharin M: Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood. J Pediatr Endocrinol Metab. 2006, 19: 75-80.

Leet AI, Magur E, Lee JS, Wientroub S, Robey PG, Collins MT: Fibrous dysplasia in the spine: prevalence of lesions and association with scoliosis. J Bone Joint Surg Am. 2004, 86-A (3): 531-537.

Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT: Letrozole Treatment of Precocious Puberty in Girls with the McCune-Albright Syndrome: A Pilot Study. J Clin Endocrinol Metab. 2007, 92: 2100-2106. 10.1210/jc.2006-2350.

Feuillan PP: Treatment of sexual precocity in girls with the McCune-Albright syndrome. Sexual precocity: etiology, diagnosis and management. Edited by: Grave GD, Cutler GB. 1993, New York: Raven Press, 243-251.

Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH: Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. The Journal of pediatrics. 2003, 143: 60-66. 10.1016/S0022-3476(03)00128-8.

Congedo V, Celi FS: Thyroid disease in patients with McCune-Albright syndrome. Pediatr Endocrinol Rev. 2007, 4 (Suppl 4): 429-433.

Akintoye SO, Kelly MH, Brillante B, Cherman N, Turner S, Butman JA, Robey PG, Collins MT: Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome. J Clin Endocrinol Metab. 2006, 91: 2960-2966. 10.1210/jc.2005-2661.

Chanson P, Salenave S, Orcel P: McCune-Albright syndrome in adulthood. Pediatr Endocrinol Rev. 2007, 4 (Suppl 4): 453-462.

Galland F, Kamenicky P, Affres H, Reznik Y, Pontvert D, Le Bouc Y, Young J, Chanson P: McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. J Clin Endocrinol Metab. 2006, 91: 4957-4961. 10.1210/jc.2006-0561.

Ehrig U, Wilson DR: Fibrous dysplasia of bone and primary hyperparathyroidism. Ann Intern Med. 1972, 77: 234-238.

Leslie WD, Reinhold C, Rosenthall L, Tau C, Glorieux FH: Panostotic fibrous dysplasia. A new craniotubular dysplasia. Clinical nuclear medicine. 1992, 17: 556-560. 10.1097/00003072-199207000-00005.

Feuillan PP: McCune-Albright syndrome. Curr Ther Endocrinol Metab. 1997, 6: 235-239.

Defilippi C, Chiappetta D, Marzari D, Mussa A, Lala R: Image diagnosis in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2006, 19 (Suppl 2): 561-570.

Silva ES, Lumbroso S, Medina M, Gillerot Y, Sultan C, Sokal EM: Demonstration of McCune-Albright mutations in the liver of children with high gammaGT progressive cholestasis. Journal of hepatology. 2000, 32: 154-158. 10.1016/S0168-8278(00)80202-0.

Zimmerman D: Fetal and neonatal hyperthyroidism. Thyroid. 1999, 9: 727-733.

Schwartz RA, Spicer MS, Leevy CB, Ticker JB, Lambert WC: Cutaneous fibrous dysplasia: an incomplete form of the McCune-Albright syndrome. Dermatology (Basel, Switzerland). 1996, 192: 258-261.

Pierini AM, Ortonne JP, Floret D: [Cutaneous manifestations of McCune-Albright syndrome: report of a case (author's transl)]. Annales de dermatologie et de venereologie. 1981, 108: 969-976.